Abstract
Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.
Keywords:
Breast cancer; Denosumab; Postmenopausal osteoporosis.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Practice Guideline
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bone Density / drug effects
-
Bone Density Conservation Agents / administration & dosage
-
Bone Density Conservation Agents / economics
-
Bone Density Conservation Agents / therapeutic use*
-
Bone Neoplasms / prevention & control
-
Bone Neoplasms / secondary
-
Bone Remodeling / drug effects
-
Breast Neoplasms / pathology
-
Denosumab / administration & dosage
-
Denosumab / economics
-
Denosumab / therapeutic use*
-
Disease Progression
-
Female
-
Fractures, Bone / economics
-
Fractures, Bone / prevention & control
-
Humans
-
Injections, Subcutaneous
-
Osteoporosis, Postmenopausal / drug therapy*
-
Postmenopause / drug effects
-
Safety
Substances
-
Bone Density Conservation Agents
-
Denosumab